Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

Andrew J. Armstrong, MD
Published: Tuesday, Oct 24, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Currently, there are 2 lead candidates for the AR-V7 test—the Epic Sciences AR-V7 Test from Genomic Health, and a Johns Hopkins assay that is based on RNA.

Neither of these studies are FDA approved, but both are undergoing prospective validation.
 


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Currently, there are 2 lead candidates for the AR-V7 test—the Epic Sciences AR-V7 Test from Genomic Health, and a Johns Hopkins assay that is based on RNA.

Neither of these studies are FDA approved, but both are undergoing prospective validation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x